Entities / Company
KALA BIO, Inc..
Czech company
- Reports this week
- 0
- Active events
- 0
- Connections
- 18
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
KALA BIO, Inc. ownership structure as of September 5, 2025, includes 40% owned by retail investors, 26% by hedge funds, and Baker Bros. Advisors LP as the largest shareholder.Some support1 report1 development inside
-
KALA BIO, Inc. stock is trading on the Nasdaq exchange, with institutional inflows and outflows impacting its price.Some support5 reports
One to three months ago
Gone quiet
No new reports in 90+ days-
KALA BIO, Inc. received Orphan Drug and Fast Track designations from the Food and Drug Administration on September 3, 2025.Some support3 reports
-
KALA BIO, Inc. appointed Todd Bazemore as CEO and confirmed the CHASE trial is Phase 2b, leveraging the MSC-S platform.Some support1 report
-
Kala BIO hosted an event featuring a director from Scripps Clinic Medical Group on July 7, 2025.Speculative1 report
-
Analyst coverage sparked interest in stocks involving Kala and Graham on July 25, 2025.Some support2 reports1 development inside
No events began in the chosen period. Widen it, or reset.
Around KALA BIO, Inc. this week
News at the entities that move KALA BIO, Inc. most-
MSC StructuralMSC's ship itinerary is being adjusted, with visits to La Rochelle and Le Havre cancelled due to weather and strikes, while Vigo is added.Moves KALA BIO, Inc.
-
Nasdaq Shared contextThe First Trust RBA American Industrial Renaissance ETF trades on the electronic stock exchange.Moves KALA BIO, Inc.
-
Ford Mentioned togetherProtests erupted in multiple Ontario cities, including Ottawa, Thunder Bay, and London, over education funding and government policies.Moves KALA BIO, Inc.
Connections
The 4 strongest of 18, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
MSC Structural
Kala's pipeline development for ocular diseases is structurally dependent on MSC's MSC-S platform.
-
Nasdaq Shared context
Kala Bio is a company that operates and is listed on the Nasdaq stock exchange.
-
Ashley Weaver Mentioned together
No discernible relationship established between KALA BIO, Inc. and Ashley Weaver based on the provided evidence.
-
Ford Mentioned together
Evidence is insufficient to establish any relationship between KALA BIO, Inc. and Ford.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
1 eventJune 2026
5 events- KALA BIO, Inc. ownership structure as of September 5, 2025, includes 40% owned by retail investors, 26% by hedge funds, and Baker Bros. Advisors LP as the largest shareholder.
- KALA BIO, Inc. received Orphan Drug and Fast Track designations from the Food and Drug Administration on September 3, 2025.
- KALA BIO, Inc. appointed Todd Bazemore as CEO and confirmed the CHASE trial is Phase 2b, leveraging the MSC-S platform.
- Kala BIO hosted an event featuring a director from Scripps Clinic Medical Group on July 7, 2025.
- Analyst coverage sparked interest in stocks involving Kala and Graham on July 25, 2025.